Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of subcutaneous GW906 (SAL0132) for long-term safety and efficacy in primary hypertension
CTR20262143Phase 2Active
- Sponsor
- Gowell
- Start
- May 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GW906 in essential hypertension, sponsored by Gowell. Started May 2026; status: active.
02
Drugs
GW906
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20262143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262143.